Premium Collides with Fragile Profitability
Redcare Pharmacy trades at a steep 43.8x forward P/E, but persistent earnings weakness and a -1.4% operating margin keep its premium under pressure. Double-digit revenue growth remains intact, yet profitability and capital returns are structurally weak. Market stress is concentrated in extreme volatility and a sharp -84.6% drawdown. A more anchored valuation would require sustained margin improvement and greater stability.
Published by AssetNext · 2026-04-14
| Date | Signal | Peer score | Drawdown | 21d vs sector |
|---|---|---|---|---|
| 2026-04-23 | Weak businesses rallying | 33 | -62.9% | +47.0% |
| 2026-04-16 | Weak businesses rallying | 34 | -63.5% | +22.6% |
| 2026-04-07 | Structural weakness emerging | 35 | -73.3% | -15.6% |
Break down RDC.DE's structural position across all peer dimensions with the interactive app.